Sign In
Buy HOTH
$1.36
+0 (+0%)
At Close: Jun 03, 2026
Wall Street Suggests Buying These 2 Falling Knives
03:43pm, Sunday, 14'th Jun 2020
Their share prices are predicted to bounce back strongly Continue reading...
The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations
12:00am, Friday, 12'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 11)
ADC Therapeutics SA (NYSE:...
Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions
01:08pm, Monday, 08'th Jun 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Applicati
Developing a COVID-19 Vaccine Quickly Proving to be a Daunting Task But Progress Still Expected
01:50pm, Wednesday, 03'rd Jun 2020
PALM BEACH, Florida, Jun 03, 2020 (PR Newswire Europe via COMTEX) --
- Financialnewsmedia.com News Commentary PALM BEACH, Florida, June 3, 2020 /PRNewswire/...
Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline
12:00pm, Wednesday, 03'rd Jun 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today provided an update on its pipeline of therapeutics including six compounds in various stages of clinical development, targeti
Hoth Therapeutics Announces Closing of Public Offering of Common Stock
05:50pm, Wednesday, 27'th May 2020
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of 1,818,182 shares
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board
12:00pm, Friday, 22'nd May 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor of Ho
Hoth Announces Pricing of Public Offering of Shares of Common Stock
01:07am, Friday, 22'nd May 2020
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a p
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
12:00am, Friday, 22'nd May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 21)
ADC Therapeutics SA (NYSE:...
Hoth Announces Proposed Public Offering of Common Stock
08:01pm, Thursday, 21'st May 2020
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public offering. T
Hoth Therapeutics Licenses Novel Peptide COVID-19 Therapeutic
12:00pm, Wednesday, 20'th May 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a nove
Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment
12:00pm, Monday, 18'th May 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, pa
Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.
01:40pm, Tuesday, 05'th May 2020
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc ("Zylö").
Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloV
Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax for development and progression into pre-c
